source
- Ultra-low dose nivolumab shows survival benefit for head and neck cancer patients in IndiaResearchers presented data at the American Society of Clinical Oncology meeting showing that an ultra‑low dose of the PD‑1 inhibitor nivolumab, given with chemotherapy, extended survival for patien…
- Ivonescimab cuts death risk by one-third in Chinese lung cancer trial, adds four-month survivalA trial in China evaluated ivonescimab combined with chemotherapy in patients newly diagnosed with advanced non-small cell lung cancer. The study was presented at the American Society of Clinical O…